Sebastian Dintner
Overview
Explore the profile of Sebastian Dintner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
346
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Enke J, Reitsam N, Dintner S, Liesche-Starnecker F, Schaller T, Decker J, et al.
J Nucl Med
. 2025 Jan;
66(2):245-249.
PMID: 39819694
Despite the addition of immune checkpoint blockade to first-line chemotherapy, the prognosis for patients with small cell lung cancer (SCLC) is still devastating. For the subset of SCLC with somatostatin...
2.
Mogele T, Hock M, Sommer F, Friedrich L, Sommer S, Schmutz M, et al.
Cancers (Basel)
. 2025 Jan;
16(24.
PMID: 39766073
Background/objectives: Locally advanced rectal cancer is treated with neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal excision (TME). As this approach achieves complete pathologic remissions (pCR) in approximately 30% of patients,...
3.
Kuhlen M, Schaller T, Dintner S, Stadler N, Hofmann T, Schmutz M, et al.
Int J Mol Sci
. 2024 Nov;
25(21).
PMID: 39519042
Undifferentiated embryonal sarcoma of the liver is a rare mesenchymal malignancy that predominantly occurs in children. The relationship between this tumor entity and germline pathogenic variants (PVs) remains undefined. Here,...
4.
Menzel M, Martis-Thiele M, Goldschmid H, Ott A, Romanovsky E, Siemanowski-Hrach J, et al.
Eur J Cancer
. 2024 Sep;
211:114306.
PMID: 39293347
Introduction: Whole Exome Sequencing (WES) has emerged as an efficient tool in clinical cancer diagnostics to broaden the scope from panel-based diagnostics to screening of all genes and enabling robust...
5.
Krebs M, Haller F, Sporl S, Gerhard-Hartmann E, Utpatel K, Maurus K, et al.
Eur J Cancer
. 2024 Jun;
207:114144.
PMID: 38852290
Purpose: Providing patient access to precision oncology (PO) is a major challenge of clinical oncologists. Here, we provide an easily transferable model from strategic management science to assess the outreach...
6.
Blasi M, Kuon J, Luders H, Misch D, Kauffmann-Guerrero D, Hilbrandt M, et al.
Eur J Cancer
. 2024 May;
205:114130.
PMID: 38789333
No abstract available.
7.
Blasi M, Kuon J, Luders H, Misch D, Kauffmann-Guerrero D, Hilbrandt M, et al.
Eur J Cancer
. 2024 Jan;
199:113556.
PMID: 38271745
Background: The efficacy of checkpoint inhibitors for non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METΔ14ex) remains controversial. Materials And Methods: 110 consecutive METΔ14ex NSCLC patients receiving first-line...
8.
Dintner S, Schmutz M, Sommer S, Langer A, Hirschbuhl K, Claus R, et al.
Pathologie (Heidelb)
. 2023 Nov;
44(Suppl 3):155-159.
PMID: 37975919
The diagnosis of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), originally based on morphological assessment alone, has to bring together more and more disciplines. Today, modern AML/MDS diagnostics rely...
9.
Sommer S, Schmutz M, Schaller T, Mayr P, Dintner S, Markl B, et al.
Cancer Rep (Hoboken)
. 2023 Nov;
7(1):e1916.
PMID: 37950626
Background: Inflammatory myofibroblastic tumor (IMTs) are rare mesenchymal neoplasms with slow growth. Resection is considered as therapeutic standard, with chemotherapy being insufficiently effective in advanced disease. ALK translocations are present...
10.
Schweizer L, Schaller T, Zwiebel M, Karayel O, Muller-Reif J, Zeng W, et al.
EMBO Mol Med
. 2023 Jul;
15(9):e17459.
PMID: 37519267
SARS-CoV-2 may directly and indirectly damage lung tissue and other host organs, but there are few system-wide, untargeted studies of these effects on the human body. Here, we developed a...